NetworkNewsBreaks – TC Biopharm (Holdings) PLC (
Post# of 10
(Total Views: 68)
Posted On: 09/09/2024 5:59:24 PM
NetworkNewsBreaks – TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Plans Preclinical Studies for Treatment of Monkey Pox
TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, is focused on beginning Proof of Concept preclinical studies to evaluate its lead therapeutic TCB 008 for treatment in monkey pox. According to the announcement, TCBP will partner with a leading infectious disease center or university associated with a similar organization to advance the studies as quickly as possible.
“There are a number of academic papers highlighting a successful immune response to viral infection being heavily reliant on the presence of gamma delta t-cells,” said TC BioPharm CEO Bryan Kobel in the press release. “We continue to look at avenues to expand the therapeutic applications for TCB008, and moving into rapid response for aggressive viral infections is an arena we believe our therapeutic can be immediately impactful. The ability to deliver a frozen/thawed product to these patients to prevent not just the death or extended viral infection in these patients, but also potentially slow the spread of the infectious disease and contain the issue from becoming a global pandemic, would represent a massive global opportunity and market size. We look forward to updating investors as we further this program.”
NOTE TO INVESTORS: The latest news and updates relating to TCBP are available in the company’s newsroom at https://nnw.fm/TCBP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, is focused on beginning Proof of Concept preclinical studies to evaluate its lead therapeutic TCB 008 for treatment in monkey pox. According to the announcement, TCBP will partner with a leading infectious disease center or university associated with a similar organization to advance the studies as quickly as possible.
“There are a number of academic papers highlighting a successful immune response to viral infection being heavily reliant on the presence of gamma delta t-cells,” said TC BioPharm CEO Bryan Kobel in the press release. “We continue to look at avenues to expand the therapeutic applications for TCB008, and moving into rapid response for aggressive viral infections is an arena we believe our therapeutic can be immediately impactful. The ability to deliver a frozen/thawed product to these patients to prevent not just the death or extended viral infection in these patients, but also potentially slow the spread of the infectious disease and contain the issue from becoming a global pandemic, would represent a massive global opportunity and market size. We look forward to updating investors as we further this program.”
NOTE TO INVESTORS: The latest news and updates relating to TCBP are available in the company’s newsroom at https://nnw.fm/TCBP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)